Browse by author
Lookup NU author(s): Dr Elizabeth Jones, Dr Lesley Kay
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Background: Axial spondyloarthropathy typically has its onset in early adulthood and can impact significantly on quality of life. In the UK, biologic anti-tumour necrosis factor therapy is recommended for patients who are unresponsive to non-steroidal anti-inflammatory drugs. There remain several unresolved issues about the long-term safety and quality of life outcomes of biologic treatment in axial spondyloarthropathy. Long-term "real-world" surveillance data are required to complement data from randomised controlled trials.Methods/Design: We are conducting a UK-wide prospective cohort study of patients with axial spondyloarthropathy who are naive to biologic therapy at the time of recruitment. Those about to commence anti-tumour necrosis factor biologic therapy will enter a "biologic" sub-cohort with other patients assigned to a "non-biologic" sub-cohort. The primary objective is to determine whether the use of biologic therapy is associated with an increased risk of serious infection, while secondary objectives are to assess differences in malignancy, serious comorbidity, all-cause mortality but also assess impact on specific clinical domains (physical health, mental health and quality of life) including work outcomes between biologic and non-biologic patient cohorts. Patients will be followed-up for up to 5 years. Data are obtained at baseline and at standard clinical follow-up visits - at 3, 6 and 12 months and then annually for the biologic cohort and annually for the non-biologic cohort. This study will also collect biological samples for genetic analysis.Discussion: Although biologic therapy is widely used for ankylosing spondylitis patients who are unresponsive to non-steroidal anti-inflammatory drugs, the majority of the available safety information comes from rheumatoid arthritis, where increased infection risk has consistently been shown. However, given the typical demographic differences between rheumatoid arthritis and axial spondyloarthropathy patients, it is important to develop an epidemiologically rigorous cohort of patients receiving biologic therapy to effectively evaluate outcomes with regard not only to safety but also to quantify benefits across clinical, psychosocial and work outcomes.Clinical trial registration: This is an observational cohort study and clinical trial registration was not required or obtained
Author(s): Macfarlane GJ, Barnish MS, Jones EA, Kay L, Keat A, Meldrum KT, Pathan E, Sturrock RD, Zabke C, McNamee P, Jones GT
Publication type: Article
Publication status: Published
Journal: BMC Musculoskeletal Disorders
Year: 2015
Volume: 16
Online publication date: 11/11/2015
Acceptance date: 04/11/2015
Date deposited: 14/04/2016
ISSN (electronic): 1471-2474
Publisher: BioMed Central Ltd
URL: http://dx.doi.org/10.1186/s12891-015-0805-x
DOI: 10.1186/s12891-015-0805-x
Altmetrics provided by Altmetric
